The alkylating agent melphalan is actively utilized in MM therapy; however, dose-limiting toxicities and development of resistance limits its use.
Introduction
Multiple myeloma (MM) remains incurable due to the development of a drug resistant phenotype after prolonged therapy (1, 2) . For many years, combined melphalan (mustard-L-phenylalanine) and prednisone has been a mainstay of MM treatment in the non-transplant candidates. In transplant candidates, a treatment regimen comprising a high-dose melphalan (HDM) in conjunction with autologous stem cell transplantation (ASCT) has improved progression-free and overall survival in MM patients (3) (4) (5) . More recent studies have combined melphalan and steroids with several novel agents such as bortezomib, thalidomide, or lenalidomide, as initial therapy of elderly newly diagnosed patients and have improved response extent and frequency, as well as prolonged progression free an overall survival (6) (7) (8) (9) (10) (11) (12) . In a parallel fashion, integration of these novel therapies into the transplant paradigm as induction, consolidation, and maintenance has further improved outcome in this setting (13, 14) . These studies exemplify the utility of melphalan in the current MM therapy, and provided impetus for the development of melphalan prodrug to increase tumor specificity, reduce toxicity and prevent drug-resistance.
Pharmacological screening of alkylating oligopeptides led to the identification of a novel melphalan-containing prodrug mel-flufen (L-melphalanylp-L-fluoro phenylalanine ethyl ester), a molecular entity with a more potent antitumor activity than parental drug melphalan despite identical alkylating capacity ( Fig 1A) (15) (16) (17) . Mel-flufen is rapidly incorporated into the tumor cells, followed by intracellular hydrolysis which in part is mediated by aminopeptidase N Studies using solid tumor cell models showed that treatment with mel-flufen causes at least a 10-fold higher loading of melphalan which explain its higher tumor cell cytotoxicity (15) (16) (17) 19) . To date, the mel-flufen activity against MM cells is undefined. In the present study, we examined the anti-tumor activity of mel-flufen in MM cells using both in vitro and in vivo model systems. Our studies show that mel-flufen is more potent than melphalan and can overcome resistance not only to melphalan, bur also to novel agents, providing the rationale for its clinical evaluation to improve patient outcome in MM. Cell viability, proliferation, and apoptosis assays Cell viability was assessed by using colorimetric assay with 3-(4, 5-dimethylthiozol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Calbiochem), and cell proliferation analysis in co-culture experiments with patient-derived BMSCs was performed using thymidine incorporation, as described previously (20) . Apoptosis was quantified Immunoblotting Western blot analysis was performed as previously described (22) In vitro migration and capillary-like tube structure formation assays Transwell Insert Assays (Chemicon, Billerica, MA) were utilized to measure migration, and in vitro angiogenesis was assessed by Matrigel capillary-like tube structure formation assay, as previously described (25) . For endothelial tube formation assay, human vascular endothelial cells (HUVECs) were obtained from Clonetics (Walkersville, MD) and maintained in endothelial cell growth medium-2 (EGM2 MV SingleQuots, Clonetics) containing 5% FBS.
Statistical Analysis Statistical significance of differences observed in drug-treated vs. control cultures was determined by using the Student's t test.
The minimal level of significance was P < 0.05. Tumor volume and survival in mice was measured using the GraphPad PRISM (GraphPad Software/version 5, SanDiego, CA). Isobologram analysis (26) was performed using "CalcuSyn" μM of mel-flufen load the cells with much more melphalan than can be achieved using even 100 μM of melphalan ( Fig 1B) . These data suggest that mel-flufen allows for a more rapid and higher intracellular accumulation of melphalan in MM cells than is achievable by direct exposure to equimolar doses of melphalan. Our results using MM cells is consistent with similar observation in other cancer cell lines (19) . Previous studies showed that lipophilicity and an early intracellular hydrolysis of mel-flufen by peptidases inside the cells to release melphalan contributes to achieving rapid and high intracellular concentrations of melphalan (19, 27, 28) . Earlier findings also showed that in tumor cells a limited exposure time which simulate short half-life in vivo, proved more favorable for mel-flufen than for melphalan indicating a trapping mechanism through the enzymatic activation (29) . Together, these results suggest that mel-flufen administration in MM patients is a more efficient therapeutic strategy for delivering higher Fig 1E) . These findings suggest that mel-flufen triggers both mitochondria-dependent and -independent apoptotic signaling pathways. We next examined the effects of mel-flufen in Dex-or proteasome inhibitor-resistant MM cells. We observed a significantly more potent anti-MM activity of mel-flufen than melphalan when tested against Dex-sensitive (MM.1S) and Dex-resistant (MM.1R) cells (Fig 2B) . To determine whether mel-flufen can overcome bortezomib-resistance, we utilized bortezomib-sensitive (ANBL-6.WT) and bortezomib-resistant (ANBL-6.BR) MM cell lines (40) . Interestingly, we found that while ANBL-6.WT cells are sensitive to melphalan, ANBL6.BR cells were relatively resistant to melphalan. Importantly, mel-flufen decreases the viability in ANBL-6.BR cells (Fig 2C) 
in many cancer types, and is associated with various characteristics of malignant phenotype including cell proliferation, cytokine secretion, tumor invasion and angiogenesis (18) . These studies suggest ANPEP as a viable therapeutic target in cancer (18) . As seen in Figure 3A and 3B, both ANPEP expression and activity are constitutively elevated in MM cells. Importantly, transfection of ANPEP siRNA, but not negative-control (scrambled) siRNA, significantly inhibited mel-flufen-induced apoptosis in MM.1S cells, whereas no marked difference in melphalan-induced cytotoxicity was evident (Fig 3C) . response, we performed a side-by-side comparison of melphalan and mel-flufen activity using p53-null ARP-1 cells. As expected, we found that high concentrations of melphalan (5-10 μM) are required to achieve 30%-40% cell death; importantly, mel-flufen (0.5 μM) at the concentrations 10 fold lower than melphalan (5 μM) is able to triggers significant cytotoxicity in p53-null ARP-1 MM cells (Fig 3E) . These data suggest that although mel-flufen increases p53 levels (Fig 3D) , its cytotoxic activity in MM cells is not dependent on p53. Our findings have important clinical implications, since 10-15% of MM patients have p53 mutations/deletions at presentation which confer drug resistance, and majority of patients acquire this abnormality with disease progression; a therapeutic approach using mel-flufen would allow for potent anti-MM activity even in this patient population.
An early event in the response of mammalian cells to DNA double-strand breaks is the phosphorylation of histone H2AX (γ−H2AX) at the sites in proximity to DNA breaks (42) . A robust induction of γ-H2AX was observed in mel-flufentreated MM.1R and RPMI-8226 cells (Fig 3D, middle panel early and potent induction of DNA double-strand breaks in mel-flufen-versus melphalan-treated MM.1S cells (Fig 3F) .
In order to confirm the differential induction of DNA damage by mel-flufen and melphalan, we next performed alkaline comet assay. The comet assay is a single cell gel electrophoresis assay and utilizes the principle that damaged DNA, migrates, forming a "tail", whereas undamaged DNA with intact supercoiled structure, does not migrate, forming the head of the comet. The intensity and length of the comet tail is proportional to extent of DNA damage. Results showed that even low concentrations of mel-flufen (0.5 μM) are able to trigger more potent and greater DNA damage than is observed in cells treated with higher concentrations (3 μM) of melphalan (Fig 3G, Supplementary Figure 2) . Together, these results suggest that mel-flufen is more efficient inducer of DNA damage than melphalan.
Overall, our mechanistic studies shows that 1) mel-flufen-induced cytotoxicity is facilitated via ANPEP; 2) mel-flufen triggers DNA damage associated with induction of γ-H2AX, and p53; 3) while p53 is upregulated in response to mel-flufen treatment, the cytotoxic activity of mel-flufen is not dependent on p53, suggesting that there may be a p53-independent component to mel-flufen-induced cytotoxicity; and 4) mel-flufen-induced apoptosis is associated with activation of caspases and PARP cleavage. Of note, DNA damage response signaling is linked to activation of p53/caspases signaling axis 
survival (P < 0.001) of these mice (Fig 5A and 5B, respectively) . Equimolar doses of melphalan also reduced tumor progression (Fig 5C) , albeit to a lesser extent than mel-flufen. Moreover, mel-flufen-treated mice survived for a longer time than mice receiving equimolar doses of melphalan (P < 0.01; CI =95%) (Fig 5D) .
These in vivo data confirm our in vitro findings showing more potent anti-MM activity and tumor cell selectivity of mel-flufen versus melphalan. Table) . We next examined whether mel-flufen adds to the anti-MM activity of proteasome inhibitor bortezomib and conventional anti-MM agent Dex. As with lenalidomide, the combination of mel-flufen with bortezomib or Dex triggered synergistic anti-MM activity, evidenced by a significant decrease in viability of MM.1S cells (Fig 6B and 6C , Graphs and Tables). Importantly, a similar synergism was observed between mel-flufen and lenalidomide, bortezomib, or Dex in melphalan-resistant LR5 MM cells (Fig 6D-6F , Graphs and Tables).
Although definitive evidence of decreased toxicity of combination therapy awaits
Research. 
